Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma

Niranjan J. Sathianathen, Michael C. Risk, Badrinath R. Konety

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


There are currently no reported randomized trials that characterize the staging or therapeutic benefit of performing a lymph node dissection in either bladder cancer or upper tract urothelial carcinoma. Several unanswered questions remain in this domain focused on the indications and patient selection for pelvic lymph node dissection, extent of dissection, its impact on outcome, and potential risks. However, the results of observational studies suggest that the burden of metastasis is high in both diseases when muscle invasive and performing a lymphadenectomy can provide prognostic information and yield therapeutic benefit.
Original languageEnglish (US)
Pages (from-to)215-228
Number of pages14
JournalUrologic Clinics of North America
Issue number2
StatePublished - May 2018


  • Cystectomy
  • Lymph node dissection
  • Transitional cell carcinoma
  • Urinary bladder neoplasms

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma'. Together they form a unique fingerprint.

Cite this